FLUDEOXYGLUCOSE (18F) clinical trials
3 indexed studies · 0 currently recruiting
- Ongoing, recruitingTherapeutic exploratory (Phase II)
Exploratory study evaluating the relevance of [68Ga]Ga-PentixaFor for initial staging and detection of minimal residual disease in multiple myeloma patients eligible for autologous stem cell transplantation less than 66 years included in the prospective IFM 2020-02.
This study looks at a new type of scan, called [68Ga]Ga-PentixaFor, for people under 66 with multiple myeloma. It checks how well this scan finds the cancer when first diagnosed and helps track if any cancer cells remain after treatment.
For: Multiple MyelomaFrance - Ongoing, recruitingPhase II and Phase III (Integrated)
FDG-PET/CT versus conventional CT for response monitoring in metastatic breast cancer: A pilot study for a randomized clinical trial (MONITOR-PILOT)
This study looks at different scans for people with advanced breast cancer. It compares standard CT scans with a special FDG-PET/CT scan to see which better shows how well treatment is working and if it helps people live longer and have a better quality of life.
For: Metastatic breast cancerDenmark - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A pivotal phase 3 clinical trial to assess the diagnostic performance and safety of [68Ga]Ga-PentixaFor ([68Ga]Ga-PTF), a positron emission tomography (PET) imaging agent, versus [18F]FDG PET/CT imaging, for staging of patients with confirmed marginal zone lymphoma (MZL) exemplary for CXCR4-positive malignant lymphomas: a prospective, international, multi-center, comparative, randomized, cross-over, open-label lymphoma diagnostic trial (LYMFOR).
This study compares two types of body scans for people with marginal zone lymphoma (a type of cancer). It aims to see if a newer scan ([68Ga]Ga-PentixaFor PET/CT) is better or as good as the standard scan ([18F]FDG PET/CT) at finding cancer cells in the body.
For: Marginal Zone LymphomaGermany · Italy · Spain